Can erythropoietin therapy improve survival?
Glaspy J, Dunst J
Oncology 2004;67 Suppl 1:5-11.
Review by
A restrictive use of both autologous donation and recombinant human erythropoietin is an efficient policy for primary total hip or knee arthroplasty.
Couvret C, Laffon M, Baud A, Payen V, Burdin P, Fusciardi J
Anesth Analg 2004;99:262-271.
Review by
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
Henke M, Laszig R, Rube C, et al.
Lancet 2003;362:1255-1260.
Review by
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial.
Glossmann JP, Engert A, Wassmer G, et al.
Ann Hematol 2003;82(8):469-475.
Review by Henry DH
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response... Read More
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659